SELLAS Life Sciences Group, Inc. Retained Earnings
SELLAS Life Sciences Group, Inc. (SLS) had Retained Earnings of -$293.00 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-11
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$293.00M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$283.39M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$274.99M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$267.33M.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2026-06-30 | -$293.00M 10-Q · filed 2026-08-11 | |
| 2026-03-31 | -$283.39M 10-Q · filed 2026-05-12 | |
| 2025-12-31 | -$274.99M 10-Q · filed 2026-08-11 | |
| 2025-09-30 | -$267.33M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | -$260.54M 10-Q · filed 2025-08-12 | |
| 2025-03-31 | -$253.94M 10-Q · filed 2025-05-13 | |
| 2024-12-31 | -$248.13M 10-K · filed 2026-03-19 | |
| 2024-09-30 | -$241.39M 10-Q · filed 2024-11-13 | |
| 2024-06-30 | -$234.28M 10-Q · filed 2024-08-13 | |
| 2024-03-31 | -$226.81M 10-Q · filed 2024-05-14 | |
| 2023-12-31 | -$217.24M 10-K · filed 2025-03-20 | |
| 2023-09-30 | -$209.11M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | -$199.84M 10-Q · filed 2023-08-10 | |
| 2023-03-31 | -$191.00M 10-Q · filed 2023-05-11 | |
| 2022-12-31 | -$179.90M 10-K · filed 2024-03-28 | |
| 2022-09-30 | -$170.78M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | -$163.76M 10-Q · filed 2022-08-11 | |
| 2022-03-31 | -$155.35M 10-Q · filed 2022-05-12 | |
| 2021-12-31 | -$138.60M 10-K · filed 2023-03-16 | |
| 2021-09-30 | -$132.00M 10-Q · filed 2021-11-12 | |
| 2021-06-30 | -$124.92M 10-Q · filed 2021-08-12 | |
| 2021-03-31 | -$120.31M 10-Q · filed 2021-05-13 | |
| 2020-12-31 | -$117.90M 10-K · filed 2022-03-31 | |
| 2020-09-30 | -$114.19M 10-Q · filed 2020-11-13 | |
| 2020-06-30 | -$109.72M 10-Q · filed 2020-08-13 | |
| 2020-03-31 | -$105.29M 10-Q · filed 2020-05-14 | |
| 2019-12-31 | -$101.15M 10-K · filed 2021-03-23 | |
| 2019-09-30 | -$93.73M 10-Q · filed 2019-11-14 | |
| 2019-06-30 | -$89.53M 10-Q · filed 2019-08-14 | |
| 2019-03-31 | -$86.39M 10-Q · filed 2019-05-15 | |
| 2018-12-31 | -$81.86M 10-K · filed 2020-03-13 | |
| 2018-09-30 | -$68.53M 10-Q · filed 2018-11-14 | |
| 2018-06-30 | -$68.24M 10-Q · filed 2018-08-14 | |
| 2018-03-31 | -$62.18M 10-Q · filed 2018-05-15 | |
| 2017-12-31 | -$54.19M 10-K · filed 2019-03-22 | |
| 2017-09-30 | -$329.13M 10-Q · filed 2017-11-09 | |
| 2017-06-30 | -$323.05M 10-Q · filed 2017-08-14 | |
| 2016-12-31 | -$30.43M 10-K · filed 2018-04-13 | -$302.93M 10-Q · filed 2017-08-14 |
| 2011-06-30 | -$60.97M 10-Q · filed 2011-08-15 | |
| 2010-12-31 | -$55.74M 10-Q · filed 2011-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |